Antiangiogenesis Induced Tumor Cavitation in Lung Cancer  by Kelly, Ronan J. et al.
IMAGE OF THE MONTH
Antiangiogenesis Induced Tumor Cavitation
in Lung Cancer
Ronan J. Kelly, MD,* Oleh Hnatiuk, MD,† and Giuseppe Giaccone, MD, PhD*
(J Thorac Oncol. 2009;4: 1573–1575)
A 52-year-old Chinese female never smoker presented inJune 2009 with multiple bilateral cavitations and a large
tumor in the left lower lobe (Figures 1 and 2). She was
diagnosed with stage IV adenocarcinoma in December 2006
with multiple pulmonary nodules and a destructive lesion at
C5 (Figure 3). Biopsies of the left lower lobe and C5
confirmed a metastatic poorly differentiated adenocarcinoma
of the lung. The patient was commenced originally on erlo-
tinib in January 2007 followed by carboplatin/paclitaxel
(February 2008) and pemetrexed (July 2008). Bevacizumab
(15 mg/kg every 3 weeks) was added to the erlotinib in March
2007 and was maintained continuously throughout both sec-
ond and third line chemotherapeutic regimens until Novem-
ber 2008 when brain metastases were diagnosed. The diffuse
cavitating lung lesions were first found in July 2007. Three
negative bronchoscopies and numerous blood and sputum
cultures ruled out tuberculosis, opportunistic infection, para-
sitic infestation, and other potential causes of cavitation.
Tumor cavitation induced by antiangiogenic agents is com-
mon occurring in 16% of patients with lung cancer.1,2
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FIGURE 1. Computed tomography (CT) thorax (June 2009)
showing diffuse bilateral cavitations and a large tumor in the
left lower lobe.
FIGURE 2. Positron emission tomography/computed to-
mography (PET/CT) thorax (June 2009) showing diffuse bi-
lateral cavitations and a large tumor in the left lower lobe.
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FIGURE 3. Computed tomography (CT) thorax (December
2006) demonstrating innumerable pulmonary nodules and
the main lung mass in the left lower lobe.
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